Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Finished Goods (2016 - 2021)

Medifast's Finished Goods history spans 9 years, with the latest figure at $100.7 million for Q3 2021.

  • For Q3 2021, Finished Goods rose 387.59% year-over-year to $100.7 million; the TTM value through Sep 2021 reached $100.7 million, up 387.59%, while the annual FY2020 figure was $29.9 million, 4.65% down from the prior year.
  • Finished Goods reached $100.7 million in Q3 2021 per MED's latest filing, up from $73.1 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $100.7 million in Q3 2021 to a low of $10.5 million in Q3 2017.
  • Average Finished Goods over 5 years is $30.3 million, with a median of $27.5 million recorded in 2018.
  • Peak YoY movement for Finished Goods: crashed 38.84% in 2020, then surged 387.59% in 2021.
  • A 5-year view of Finished Goods shows it stood at $13.4 million in 2017, then soared by 90.27% to $25.5 million in 2018, then grew by 22.76% to $31.3 million in 2019, then fell by 4.65% to $29.9 million in 2020, then soared by 237.22% to $100.7 million in 2021.
  • Per Business Quant, the three most recent readings for MED's Finished Goods are $100.7 million (Q3 2021), $73.1 million (Q2 2021), and $40.5 million (Q1 2021).